Efficacy News and Research

RSS

$Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma$

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies at a median of nearly 35 months of follow-up, according to the results of a new trial presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

10 Dec 2025

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

Researchers profiled a terminally sterilized probiotic-fermented MFH beverage and identified aporphine alkaloids and flavonoids with favorable predicted ADMET properties. Integrated network pharmacology, molecular docking, and 100-ns MD simulations suggest multi-target engagement of metabolic-inflammatory pathways relevant to obesity and type 2 diabetes.

9 Dec 2025

SwRI and Trinity researchers work on next-generation intranasal therapy for PTSD

Southwest Research Institute (SwRI) and Trinity University are developing an intranasal (IN) drug-device combination to treat post-traumatic stress disorder (PTSD).

9 Dec 2025

Laughing gas shows fast antidepressant effects in early clinical trials

A systematic review and meta-analysis in eBioMedicine shows that nitrous oxide can rapidly reduce depressive symptoms within hours, particularly at higher doses, but effects are short-lived after single treatments. Repeated dosing appears to extend and strengthen antidepressant benefits, although the current evidence is based on small, early-phase trials with limited long-term safety data.

8 Dec 2025

Combination therapy may boost survival for people with aggressive lymphoma

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma.

8 Dec 2025

Lubiprostone shows signs of slowing kidney function decline in chronic kidney disease

In adults with stage IIIb–IV chronic kidney disease, the constipation drug lubiprostone did not reduce gut-derived uremic toxins but preserved creatinine-based kidney function over 24 weeks. The benefit was linked to microbiome remodeling, increased polyamine production, and improved mitochondrial function rather than toxin lowering.

8 Dec 2025

Intellicule secures $217,941 SBIR Phase I grant to develop biomolecular modeling software

Intellicule, a software company whose solutions determine the 3D structures of biomolecules imaged with cryogenic-electron microscopy (cryo-EM), has received a $217,941 Small Business Innovation Research (SBIR) Phase I grant from the National Institutes of Health.

8 Dec 2025

New combination treatment offers significant benefits for people with recurring grade 3 astrocytoma

Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new combination treatment plan helped people with recurring grade 3 astrocytoma, an aggressive form of brain cancer, live longer.

8 Dec 2025

Chemotherapy-free combination treatment outperforms traditional regimens in patients with Ph+ ALL

A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study.

7 Dec 2025

Virtual diet and exercise program shows promise in reducing lymphoma treatment side effects

Patients undergoing treatment for lymphoma often experience adverse side effects that can be so severe that they stop or slow treatment.

7 Dec 2025

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor.

7 Dec 2025

Fixed-duration therapy works as effectively as continuous treatment for chronic lymphocytic leukemia

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time.

7 Dec 2025

Exa-cel shows complete success in early pediatric trials for sickle cell disease and beta-thalassemia

Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an effective cure for beta-thalassemia and sickle cell disease in children younger than 12.

6 Dec 2025

$New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer$

New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, investigators found that a single dose of the alpha-emitting radionuclide 211At (astatine) was both well-tolerated and effective, achieving disease control without molecularly targeted drugs.

5 Dec 2025

New combination treatment helps people with recurring grade 3 astrocytoma, trial shows

5 Dec 2025

Engineered herpes virus activates potent immune responses against glioblastoma

Researchers at Mass General Brigham have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells.

4 Dec 2025

Researchers capture high-resolution footage of flu viruses entering human cells

For the first time, researchers have observed live and in high resolution how influenza viruses infect living cells. This was possible thanks to a new microscopy technique, which could now help to develop antiviral therapies in a more targeted manner.

4 Dec 2025

Organ-on-a-chip system reveals how aging weakens vaccine-driven anti-cancer immunity

Dr. Vadim Jucaud's lab at the Terasaki Institute has introduced a new organ-on-a-chip platform that recapitulates age-dependent immune responses, offering a more accurate testing bed for evaluating cancer vaccine performance in older adults, the population most affected by cancer and often overlooked in traditional preclinical testing.

4 Dec 2025

E-visits resolve common health issues with low follow-up rates

Researchers compare the efficacy of e-visits in clinical settings where other types of visits are available.

4 Dec 2025

Previous
1
...
39
40
41
42
43
44
45
...
1332
Next

Efficacy News and Research

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

SwRI and Trinity researchers work on next-generation intranasal therapy for PTSD

Laughing gas shows fast antidepressant effects in early clinical trials

Combination therapy may boost survival for people with aggressive lymphoma

Lubiprostone shows signs of slowing kidney function decline in chronic kidney disease

Intellicule secures $217,941 SBIR Phase I grant to develop biomolecular modeling software

New combination treatment offers significant benefits for people with recurring grade 3 astrocytoma

Chemotherapy-free combination treatment outperforms traditional regimens in patients with Ph+ ALL

Virtual diet and exercise program shows promise in reducing lymphoma treatment side effects

Evidence grows for pirtobrutinib as a safer and effective alternative for CLL and SLL

Fixed-duration therapy works as effectively as continuous treatment for chronic lymphocytic leukemia

Exa-cel shows complete success in early pediatric trials for sickle cell disease and beta-thalassemia

New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer

New combination treatment helps people with recurring grade 3 astrocytoma, trial shows

Engineered herpes virus activates potent immune responses against glioblastoma

Researchers capture high-resolution footage of flu viruses entering human cells

Organ-on-a-chip system reveals how aging weakens vaccine-driven anti-cancer immunity

E-visits resolve common health issues with low follow-up rates

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News